Antiviral Effect, Safety, & Pharmacokinetics of once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-Naive Patients for 24 weeks as Combination Therapy with Pegylated Interferon-a 2a and Ribavirin

ID Number 08-1348

Principal Investigator(s)
Douglas Dieterich

Department(s) or Division(s)
Liver Diseases

Description

The purpose of this study is to see how well the study drug, called BI 201335 NA, works and how safe it is to use daily in combination with the standard of care drugs, Pegasys® and Copegus®, in patients with the Hepatitis C Virus (HCV).



Contact Information
Douglas Dieterich, MD
douglas.dieterich@mountsinai.org

Recruiting Patients: No